About
CorFlow Therapeutics AG is a Swiss medical technology company based in Baar, specializing in diagnostic and therapeutic solutions for microvascular obstructions (MVO), particularly related to acute heart attacks. Founded in 2016, CorFlow aims to lead in restoring healthy microvascular blood flow in critical areas of the body. The company collaborates with prominent academic institutions and is supported by funding from the Swiss Innovation Agency. The flagship product in development is the CorFlow Controlled Flow Infusion (CoFI™) System. This system is designed to deliver therapeutic agents directly into the vasculature to diagnose and treat MVO, enhancing cardiac patient outcomes. CorFlow focuses on providing interventional cardiologists with tools to better manage microvascular disease during acute interventions, aiming to reduce complications such as heart failure and mortality. The company is also exploring broader applications of its technology beyond cardiology. CorFlow's leadership team comprises experienced professionals from the medical technology and cardiology fields, bringing valuable expertise to the development of innovative solutions for patient care.
Technologies
Keywords
Company Information
-
Employees 23
-
Founded 2016
-
Total Funding $11500027
Location
Baar, Canton of Zug, Switzerland
